Imaging correlates of molecular signatures in oligodendrogliomas

被引:113
作者
Megyesi, JF
Kachur, E
Lee, DH
Zlatescu, MC
Betensky, RA
Forsyth, PA
Okada, Y
Sasaki, H
Mizoguchi, M
Louis, DN
Cairncross, JG
机构
[1] Univ Western Ontario, Dept Clin Neurosci, London, ON, Canada
[2] Univ Western Ontario, Dept Radiol, London, ON, Canada
[3] Univ Western Ontario, Dept Oncol, London, ON, Canada
[4] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[6] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[7] Univ Calgary, Dept Oncol, Calgary, AB, Canada
[8] Tom Baker Canc Clin, Calgary, AB, Canada
[9] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[10] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA
[11] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.1158/1078-0432.CCR-04-0209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Molecular subsets of oligodendroglioma behave in biologically distinct ways. Their locations in the brain, rates of growth, and responses to therapy differ with their genotypes. Retrospectively, we inquired whether allelic loss of chromosomal arms 1p and 19q, an early molecular event and favorable prognostic marker in oligodendrogliomas, were reflected in their appearance on magnetic resonance imaging. Loss of 1p and 19q was associated with an indistinct border on T-1 images and mixed intensity signal on T-1 and T-2. Loss of 1p and 19q was also associated with paramagnetic susceptibility effect and with calcification, a common histopathological finding in oligodendrogliomas. These data encourage prospective evaluation of molecular alterations and magnetic resonance imaging characteristics of glial neoplasms.
引用
收藏
页码:4303 / 4306
页数:4
相关论文
共 20 条
[1]   Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas [J].
Bauman, GS ;
Ino, Y ;
Ueki, K ;
Zlatescu, MC ;
Fisher, BJ ;
Macdonald, DR ;
Stitt, L ;
Louis, DN ;
Cairncross, JG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03) :825-830
[2]  
Burton EC, 2002, CANCER RES, V62, P6205
[3]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[4]   SUCCESSFUL CHEMOTHERAPY FOR RECURRENT MALIGNANT OLIGODENDROGLIOMA [J].
CAIRNCROSS, JG ;
MACDONALD, DR .
ANNALS OF NEUROLOGY, 1988, 23 (04) :360-364
[5]   Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results [J].
Chahlavi, A ;
Kanner, A ;
Peereboom, D ;
Staugaitis, SM ;
Elson, P ;
Barnett, G .
JOURNAL OF NEURO-ONCOLOGY, 2003, 61 (03) :267-273
[6]   HIGH SIGNAL INTENSITY IN MR IMAGES OF CALCIFIED BRAIN-TISSUE [J].
HENKELMAN, RM ;
WATTS, JF ;
KUCHARCZYK, W .
RADIOLOGY, 1991, 179 (01) :199-206
[7]  
Ino Y, 2001, CLIN CANCER RES, V7, P839
[8]   CAVERNOUS HEMANGIOMAS - DIPOLAR SUSCEPTIBILITY ARTIFACTS AT MR-IMAGING [J].
KIM, JK ;
KUCHARCZYK, W ;
HENKELMAN, RM .
RADIOLOGY, 1993, 187 (03) :735-741
[9]  
LOUIS DN, 1992, AM J PATHOL, V141, P777
[10]   SUCCESSFUL CHEMOTHERAPY FOR NEWLY DIAGNOSED AGGRESSIVE OLIGODENDROGLIOMA [J].
MACDONALD, DR ;
GASPAR, LE ;
CAIRNCROSS, JG .
ANNALS OF NEUROLOGY, 1990, 27 (05) :573-574